Xenetic Biosciences, Inc. - Common Stock (XBIO)
4.0600
0.00 (0.00%)
Xenetic Biosciences Inc is a biotechnology company focused on developing innovative drug delivery solutions and advanced therapies to treat a range of diseases
The company leverages its proprietary technologies, including its unique drug delivery platforms and biologics, to enhance the efficacy and safety of existing medications and to create new therapeutic options. By collaborating with pharmaceutical and biotechnology partners, Xenetic aims to address unmet medical needs and improve patient outcomes through its cutting-edge research and product development efforts.

Via Benzinga · September 30, 2024

XBIO stock results show that Xenetic Biosciences met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 13, 2024

XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via InvestorPlace · May 9, 2024

XBIO stock results show that Xenetic Biosciences beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · March 22, 2024

Via Benzinga · December 5, 2023

Via Benzinga · May 16, 2023
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Gainers
Via Benzinga · June 20, 2023

Gainers NeoGames S.A. (NASDAQNGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash.
Via Benzinga · May 15, 2023

U.S. Attorney General Merrick Garland said that the Justice Department would file an appeal with the U.S. Supreme Court seeking to block the entirety of Kacsmaryk's order suspending the FDA approval of the abortion pill mifepristone.
Via Benzinga · April 13, 2023

A U.S. federal appeals court has temporarily blocked a decision by a Texas judge to halt the FDA's approval of a widely used abortion drug.
Via Benzinga · April 13, 2023

New York and California are stockpiling an alternative abortion medication in case a Texas judge's order suspending the FDA approval of the primary drug, mifepristone, goes into effect later this week.
Via Benzinga · April 12, 2023

In a new court filing, the Democratic attorneys general for 23 U.S. states have reportedly warned that a federal judge's decision to suspend the FDA's approval of mifepristone "presents devastating risks to millions of people," including those in states where abortion remains legal.
Via Benzinga · April 11, 2023

Via Benzinga · April 11, 2023

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory approval of the abortion pill mifepristone was proper. The judge is reportedly considering a request by anti-abortion groups to ban sales of the drug nationwide.
Via Benzinga · March 16, 2023

Via Benzinga · March 2, 2023

Via Benzinga · March 1, 2023

Via Benzinga · February 6, 2023
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · December 19, 2022

During Friday's trading, 293 companies set new 52-week lows.
Via Benzinga · December 16, 2022
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 30, 2022

Gainers Fast Radius, Inc. (NASDAQFSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
Via Benzinga · November 16, 2022

Gainers 1Life Healthcare (NASDAQONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1 earnings came out today.
Via Benzinga · May 4, 2022

During Friday, 125 stocks hit new 52-week lows.
Via Benzinga · October 28, 2022